搜索结果
靶点ID:TCMBANKGE005339
靶点别名:ALL; BCR1; CML; D22S11; D22S662; PHL
靶点描述:BCR activator of RhoGEF and GTPase
染色体:22
染色体位置:22q11.23
靶点类型:protein-coding
HERB_ID:-
HGNC_Link:1014
OMIM_Link:151410
Ensembl_Link:ENSG00000186716
靶点对应的植物
| ID | 拉丁名 | 药名 | 药用植物名 | 功能与主治 | 来源 | 药用部位 | 使用民族 |
|---|
靶点对应的化合物
| 化合物ID | 化合物名 | 别名 | 分子式 | 分子质量 | Smiles |
|---|
| TCMBANKIN004686 | realgar | AsHS | 0 | S[As] | |
| TCMBANKIN058519 | (-)-epigallocatechin-3-gallate; (-)-epigallocatechin 3-o-gallate;epigallocatechin gallate; galloyl-l-epigallocatechol; epigallocatechin 3-gallate; (-)-epigallocatechin gallate; | KBio2_000796; SpecPlus_000277; 50299_FLUKA; Spectrum3_000244; KBioGR_002002; 3,4,5-trihydroxybenzoic acid [(2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl] ester; MLS000758300; DivK1c_006373; (−)-Epigallocatechin gallate; EGCG; SPBio_000035; (−)-cis-2-(3,4,5-Trihydroxyphenyl)-3,4-dihydro-1(2H)-benzopyran-3,5,7-triol 3-gallate; KBioSS_000796; Epigallocatechin gallate; Spectrum4_001541; (-)-epigallocatechin 3-gallate; Tea catechin; AIDS000674; KBio2_005932; 3,4,5-trihydroxybenzoic acid [(2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3-chromanyl] ester; KBio1_001317; 989-51-5; AIDS-000674; (2R,3R)-2-(3,4,5-Trihydroxyphenyl)-3,4-dihydro-1[2H]-benzopyran-3,5,7-triol-3-(3,4,5-trihydroxybenzoate); KBio2_003364; Galloyl-L-epigallocatechol; SDCCGMLS-0066550.P001; (-)-Epigallocatechol gallate; ACon1_001054; Spectrum5_000102; Green tea extract; MEGxp0_001166; C09731; (-)-Epigallocatechin-3-o-gallate; Epigallocatechin 3-gallate; (-)-Epigallocatechin gallate; CCRIS 3729; Teavigo; [(2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl] 3,4,5-trihydroxybenzoate; Spectrum2_000168; Benzoic acid, 3,4,5-trihydroxy-, (2R,3R)-3,4-dihydro-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-2H-1-benzopyran-3-yl ester; (−)-cis-3,3′,4′,5,5′,7-Hexahydroxy-flavane-3-gallate; CHEBI:4806; (-)-epigallocatechin-3-gallate ; (-)-Epigallocatechin gallate (85% (-)-epigallocatechin gallate, 10% (-)-epigallocatechin, 5% (-)- epicatechin gallate); Catechin deriv.; SMR000449288; SPECTRUM210239; E4143_SIAL; (2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl 3,4,5-trihydroxybenzoate; Spectrum_000316; (-)-EGCG; KBio3_001128; BSPBio_001628; Epigallocatechol, 3-gallate, (-)-; Epigallocatechin-3-gallate; E4268_SIAL; epigallocatechin gallate ; epigallocatechin-3-gallate; (-)epigallocatechin-3-gallate ; EGCG; 989E515; [5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl] 2,3,4-trihydroxybenzoate; HMS2051K21; CS-1258; AC1L22IG; AK165605; Green tea polyphenols, Anagen; (-)-Epigallocatechin-3-O-gallate, United States Pharmacopeia (USP) Reference Standard; AKOS015918182; CAS-989-51-5; Epigallocatechin gallate, primary pharmaceutical reference standard; W-5069; (-)-cis-3,3',4',5,5',7-Hexahydroxy-flavane-3-gallate; (-)-Epigallocatechin gallate, analytical standard; Q-100914; DSSTox_RID_78830; AN-15867; DSSTox_GSID_29889; (-)-Epigallocatechol gallate; FT-0604392; NCGC00164319-04; Green tea extract; MEGxp0_001166; (-)-Epigallocatechin-3-o-gallate; Epigallocatechin 3-gallate; N1874; CHEBI:4806; (2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl 3,4,5-trihydroxybenzoate; BG00814299; HMS3649E08; D0E9DB; Epigallocatechol, 3-gallate, (-)-; (-)-EpigallocatechinGallateHydrate; Epigallocatechin-3-gallate; AB0014381; BQM438CTEL; NC00078; ST51055716; Epigallocatechin gallate, Pharmaceutical Secondary Standard; Certified Reference Material; SpecPlus_000277; Spectrum3_000244; (2R,3R)-5,7-Dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl-3,4,5-trihydroxybenzoate; MLS000758300; (-)-Epigallocatechin gallate (EGCG); CCG-38378; Gallic acid, 3-ester with epigallocatechol, (-)-; SR-01000946601-1; NCGC00164319-01; (-)-cis-3,4-Dihydro-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-1(2H)-benzopyran-3-yl Gallate; NCGC00164319-06; DSSTox_CID_567; MCULE-3341525983; Epigallocatechin monogallate, B; Tox21_303457; SAM001247031; 4awm; K791; 989-51-5; SR-01000946601; MFCD00075940; EGCG analogs; Galloyl-L-epigallocatechol; NCGC00164319-03; (-)-Epigallocatechin gallate, >=80% (HPLC), from green tea; Spectrum5_000102; CPD000449288; (-)-Epigallocatechin gallate; LMPK12030005; E0694; Teavigo; Epigallocatechin gallate analogs, Anagen; Epigallocatechin-3-monogallate; ACN-035233; Benzoic acid, 3,4,5-trihydroxy-, (2R,3R)-3,4-dihydro-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-2H-1-benzopyran-3-yl ester; Sunphenon; Epigallocatechin gallate(EGCG); s2250; PF-EGCg 90; 3,4-Dihydro-5,7-dihydroxy-2R-(3,4,5-trihydroxyphenyl)-2H-1-benzopyran-3R-yl-3,4,5-trihydroxybenzoate; 3,4,5-Trihydroxybenzoic acid (2R,3R)-3,4-dihydro-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-2H-1-benzopyran-3-yl ester; MLS001424000; (-)-EGCG; ZINC3870412; KBio2_000796; EGCG cpd; KBioGR_002002; Benzoic acid, 3,4,5-trihydroxy-, 3,4-dihydro-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-2H-1-benzopyran-3-yl ester, (2R-cis)-; EGCG, Anagen; NCGC00257243-01; Tox21_201468; L-Epigallocatechin gallate; cid_65064; SPBio_000035; BG01747388; Epigallocatechin gallate; KBioSS_000796; Spectrum4_001541; (-)-epigallocatechin 3-gallate; DB12116; EPIGALOCATECHIN GALLATE; ANTIOXIDANT MODEL (TRAMP) -EPIGALLOCATECHIN GALLATE; KBio2_005932; I14-7747; D0U2BH; MCULE-7760530136; 2kdh; Epigallocatechin gallate, Anagen; AOB2839; SDCCGMLS-0066550.P001; 863-65-0; FR-109; ST097428; ACon1_001054; LS-2197; CCRIS 3729; [(2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl] 3,4,5-trihydroxybenzoate; Epigallocate; GTPL7002; BDBM50070942; C22H18O11; GTPs,Anagen; SCHEMBL35258; (2R,3R)-5,7-Dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl 3,4,5-trihydroxybenzoate; MolPort-001-741-358; DivK1c_006373; KB-206444; SR-01000759328; Teavigo;; EGCG; (-)-EPIGALLOCATECHIN GALLATE (GREEN TEA EXTRACT); HY-13653; (-)-Epigallocatechin gallate, >=95%; NCGC00259019-01; Tea catechin; DS-9030; SR-01000759328-6; SR-01000759328-5; KDH; AC1Q5X0Z; KBio1_001317; (2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl 3,4,5-trihydroxyb enzoate; (2R,3R)-2-(3,4,5-Trihydroxyphenyl)-3,4-dihydro-1[2H]-benzopyran-3,5,7-triol-3-(3,4,5-trihydroxybenzoate); NVP-XAA 723; KBio2_003364; EBD2138593; FT-0082796; NCGC00164319-02; C09731; (-)-cis-2-(3,4,5-Trihydroxyphenyl)-3,4-dihydro-1(2H)-benzopyran-3,5,7-triol 3-gallate; UNII-BQM438CTEL; DTXSID1029889; WMBWREPUVVBILR-WIYYLYMNSA-N; [(2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl] 3,4,5-trihydroxybenzoate; (-)-Epigallocatehin gallate; Spectrum2_000168; (2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-1-benzopyran-3-yl 3,4,5-trihydroxybenzoate; (-)-Epigallocatechin gallate (85% (-)-epigallocatechin gallate, 10% (-)-epigallocatechin, 5% (-)- epicatechin gallate); Catechin deriv.; SMR000449288; (-)-Epigallocatechin gallat; SPECTRUM210239; Epigallocic acid; Epigallocatcchin Gallate; KS-0000132O; BP-30205; CHEMBL297453; SC-47284; Spectrum_000316; 3oob; (-)-Epigallocatechin gallate, >=97.0% (HPLC); KBio3_001128; BSPBio_001628; epigallo-catechin gallate | C22H18O11 | 458.4g/mol | C1C(C(OC2=CC(=CC(=C21)O)O)C3=CC(=C(C(=C3)O)O)O)OC(=O)C4=CC(=C(C(=C4)O)O)O |
靶点对应的疾病
| 疾病ID | 疾病名 | MeSH名 | HPO名 | UMLS名 | 疾病类型 |
|---|
| TCMBANKDI000023 | Skin and Connective Tissue Diseases; Immune System Diseases | Abnormality of the immune system | Disease or Syndrome | disease | |
| TCMBANKDI000054 | Nervous System Diseases; Mental Disorders | Abnormality of the nervous system | Disease or Syndrome | disease | |
| TCMBANKDI000066 | Mental Disorders | Abnormality of the nervous system | Mental or Behavioral Dysfunction | disease | |
| TCMBANKDI000107 | Behavior and Behavior Mechanisms | Abnormality of the nervous system | Mental or Behavioral Dysfunction | disease | |
| TCMBANKDI000166 | - | - | Neoplastic Process | disease | |
| TCMBANKDI000239 | - | - | Neoplastic Process | disease | |
| TCMBANKDI000294 | Neoplasms | - | Neoplastic Process | disease | |
| TCMBANKDI001110 | Neoplasms | Neoplasm | Neoplastic Process | disease | |
| TCMBANKDI001112 | Neoplasms; Nervous System Diseases | - | Neoplastic Process | disease | |
| TCMBANKDI002013 | - | - | Neoplastic Process | disease | |
| TCMBANKDI002138 | - | - | Neoplastic Process | disease | |
| TCMBANKDI002287 | Neoplasms; Hemic and Lymphatic Diseases | - | Neoplastic Process | group | |
| TCMBANKDI002974 | Neoplasms | - | Neoplastic Process | disease | |
| TCMBANKDI003248 | Nutritional and Metabolic Diseases; Endocrine System Diseases | Abnormality of metabolism/homeostasis; Abnormality of the endocrine system | Disease or Syndrome | disease | |
| TCMBANKDI003353 | Pathological Conditions, Signs and Symptoms; Neoplasms | - | Neoplastic Process | phenotype | |
| TCMBANKDI003864 | Hemic and Lymphatic Diseases | - | Neoplastic Process | disease | |
| TCMBANKDI004208 | Neoplasms | Neoplasm; Abnormality of the breast | Neoplastic Process | disease | |
| TCMBANKDI004680 | Pathological Conditions, Signs and Symptoms; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Musculoskeletal Diseases; Endocrine System Diseases; Hemic and Lymphatic Diseases; Cardiovascular Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI004958 | Neoplasms; Hemic and Lymphatic Diseases | - | Neoplastic Process | disease | |
| TCMBANKDI005174 | - | - | Neoplastic Process | disease | |
| TCMBANKDI005455 | Hemic and Lymphatic Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI005528 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Musculoskeletal Diseases; Nervous System Diseases | - | Congenital Abnormality | disease | |
| TCMBANKDI006084 | Neoplasms; Nervous System Diseases | - | Neoplastic Process | disease | |
| TCMBANKDI006103 | - | - | Neoplastic Process | disease | |
| TCMBANKDI006121 | Digestive System Diseases; Neoplasms | Abnormality of the digestive system; Neoplasm | Neoplastic Process | group | |
| TCMBANKDI006326 | Pathological Conditions, Signs and Symptoms | - | Congenital Abnormality | group | |
| TCMBANKDI006358 | Skin and Connective Tissue Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI007091 | Neoplasms | - | Neoplastic Process | phenotype | |
| TCMBANKDI007182 | Neoplasms; Hemic and Lymphatic Diseases | Abnormality of the immune system; Neoplasm; Abnormality of blood and blood-forming tissues | Neoplastic Process | disease | |
| TCMBANKDI007610 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Stomatognathic Diseases | Abnormality of head or neck | Congenital Abnormality | disease | |
| TCMBANKDI007618 | Hemic and Lymphatic Diseases | Abnormality of blood and blood-forming tissues | Disease or Syndrome | phenotype | |
| TCMBANKDI007737 | Pathological Conditions, Signs and Symptoms; Neoplasms | - | Neoplastic Process | disease | |
| TCMBANKDI007795 | Hemic and Lymphatic Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI007832 | Cardiovascular Diseases | - | Disease or Syndrome | phenotype | |
| TCMBANKDI008874 | - | Abnormality of head or neck | Finding | phenotype | |
| TCMBANKDI008914 | Digestive System Diseases; Nervous System Diseases; Mental Disorders | Abnormality of the digestive system | Sign or Symptom | phenotype | |
| TCMBANKDI009912 | Pathological Conditions, Signs and Symptoms | Abnormality of metabolism/homeostasis | Sign or Symptom | phenotype | |
| TCMBANKDI011315 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Nutritional and Metabolic Diseases; Skin and Connective Tissue Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI011339 | - | Abnormality of head or neck | Finding | phenotype | |
| TCMBANKDI011462 | Neoplasms; Immune System Diseases; Hemic and Lymphatic Diseases | - | Neoplastic Process | disease | |
| TCMBANKDI011743 | Neoplasms; Skin and Connective Tissue Diseases | Neoplasm; Abnormality of the breast | Neoplastic Process | group | |
| TCMBANKDI011776 | Digestive System Diseases | Abnormality of the digestive system; Constitutional symptom | Disease or Syndrome | disease | |
| TCMBANKDI013495 | Hemic and Lymphatic Diseases | Neoplasm; Abnormality of blood and blood-forming tissues | Neoplastic Process | group | |
| TCMBANKDI013728 | - | Abnormality of head or neck | Finding | phenotype | |
| TCMBANKDI015449 | Neoplasms; Immune System Diseases; Hemic and Lymphatic Diseases | - | Neoplastic Process | disease | |
| TCMBANKDI015452 | Neoplasms; Endocrine System Diseases | Abnormality of the endocrine system; Neoplasm | Neoplastic Process | disease | |
| TCMBANKDI017024 | Neoplasms; Respiratory Tract Diseases | - | Neoplastic Process | disease | |
| TCMBANKDI017183 | - | Abnormality of the integument; Abnormality of head or neck | Finding | phenotype | |
| TCMBANKDI017615 | Neoplasms | - | Neoplastic Process | disease | |
| TCMBANKDI018016 | Eye Diseases; Skin and Connective Tissue Diseases; Musculoskeletal Diseases; Immune System Diseases; Stomatognathic Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI018837 | Pathological Conditions, Signs and Symptoms; Hemic and Lymphatic Diseases | Abnormality of the immune system; Abnormality of blood and blood-forming tissues | Disease or Syndrome | disease | |
| TCMBANKDI019358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Musculoskeletal Diseases | Abnormality of limbs; Abnormality of the skeletal system | Congenital Abnormality | disease | |
| TCMBANKDI019825 | Neoplasms | - | Neoplastic Process | disease | |
| TCMBANKDI021285 | Neoplasms | Abnormality of the immune system; Neoplasm; Abnormality of blood and blood-forming tissues | Neoplastic Process | disease | |
| TCMBANKDI021339 | Hemic and Lymphatic Diseases | Abnormality of blood and blood-forming tissues | Disease or Syndrome | group | |
| TCMBANKDI021387 | Nutritional and Metabolic Diseases | Abnormality of metabolism/homeostasis | Disease or Syndrome | phenotype | |
| TCMBANKDI021716 | Nervous System Diseases; Mental Disorders | Abnormality of the nervous system | Disease or Syndrome | disease | |
| TCMBANKDI023185 | Pathological Conditions, Signs and Symptoms | Abnormality of head or neck | Finding | phenotype | |
| TCMBANKDI023556 | Stomatognathic Diseases | Abnormality of head or neck | Congenital Abnormality | disease | |
| TCMBANKDI024262 | - | - | Neoplastic Process | phenotype | |
| TCMBANKDI024535 | Neoplasms; Respiratory Tract Diseases | Neoplasm; Abnormality of the respiratory system | Neoplastic Process | disease | |
| TCMBANKDI024561 | - | - | Neoplastic Process | disease | |
| TCMBANKDI024839 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Neoplasms; Nutritional and Metabolic Diseases; Skin and Connective Tissue Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI025113 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Eye Diseases | Abnormality of the eye | Congenital Abnormality | disease | |
| TCMBANKDI026556 | Neoplasms; Hemic and Lymphatic Diseases | - | Neoplastic Process | disease | |
| TCMBANKDI026782 | Skin and Connective Tissue Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI027339 | Neoplasms; Immune System Diseases; Hemic and Lymphatic Diseases | Neoplasm; Abnormality of blood and blood-forming tissues | Neoplastic Process | disease | |
| TCMBANKDI028231 | - | Abnormality of the immune system; Neoplasm; Abnormality of blood and blood-forming tissues | Neoplastic Process | disease | |
| TCMBANKDI028385 | - | - | Neoplastic Process | disease | |
| TCMBANKDI028416 | Neoplasms | - | Neoplastic Process | disease | |
| TCMBANKDI028577 | Neoplasms; Hemic and Lymphatic Diseases | - | Neoplastic Process | disease | |
| TCMBANKDI029791 | Nutritional and Metabolic Diseases | - | Disease or Syndrome | phenotype | |
| TCMBANKDI029861 | Neoplasms; Hemic and Lymphatic Diseases | - | Neoplastic Process | disease | |
| TCMBANKDI029899 | Neoplasms; Immune System Diseases; Hemic and Lymphatic Diseases | Neoplasm; Abnormality of blood and blood-forming tissues | Neoplastic Process | group | |
| TCMBANKDI030041 | Hemic and Lymphatic Diseases | - | Neoplastic Process | disease | |
| TCMBANKDI030078 | Infections; Nervous System Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI030664 | Respiratory Tract Diseases | Abnormality of metabolism/homeostasis; Abnormality of the respiratory system | Disease or Syndrome | group | |
| TCMBANKDI031192 | Neoplasms; Male Urogenital Diseases | - | Neoplastic Process | disease | |
| TCMBANKDI031381 | Neoplasms; Hemic and Lymphatic Diseases | - | Neoplastic Process | disease | |
| TCMBANKDI031522 | Neoplasms; Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases | Abnormality of the genitourinary system; Neoplasm | Neoplastic Process | disease | |
| TCMBANKDI031523 | Hemic and Lymphatic Diseases | Abnormality of blood and blood-forming tissues | Disease or Syndrome | disease | |
| TCMBANKDI031570 | - | Abnormality of the nervous system | Mental or Behavioral Dysfunction | disease | |
| TCMBANKDI032162 | Infections | - | Disease or Syndrome | group |
滇IICP备16009434号-1 |
Dai SX Lab